Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Sep 30;101(39):e30867.
doi: 10.1097/MD.0000000000030867.

Prognostic factors for overall survival after surgical resection in patients with thymic epithelial tumors: A systematic review and meta-analysis

Affiliations
Meta-Analysis

Prognostic factors for overall survival after surgical resection in patients with thymic epithelial tumors: A systematic review and meta-analysis

Jiaduo Li et al. Medicine (Baltimore). .

Abstract

Background: Thymic epithelial tumors (TETs) originate in the thymic epithelial cell, including thymoma and thymic carcinoma. Surgical resection is the first choice for most patients. However, some studies have shown that the factors affecting the prognosis of these patients are not consistent. To evaluate prognostic factors in patients with surgically resected thymic epithelial tumors, we performed a meta-analysis.

Methods: We searched the Chinese biomedical literature database, Pubmed, Embase, Cochrane Library and other electronic databases. Studies including postoperative overall survival (OS) and predictors of TETs were included. We made a comprehensive analysis the hazard ratios (HRs) through a single proportional combination. HRs were combined using single proportion combinations.

Results: The meta-analysis included 11,695 patients from 26 studies. The pooled OS was 84% at 5 years and 73% at 10 years after TETs operation. The age as continuous-year (HR 1.04, 95% confidence interval (CI) 1.02-1.04), incomplete resection (HR 4.41, 95% CI 3.32-5.85), WHO histologic classification (B2/B3 vs A/AB/B1 HR 2.76, 95% CI 1.25-6.21), Masaoka Stage (stage III/IV vs I/II HR 2.74, 95% CI 2.12-3.55,) were the poor prognostic factors.

Conclusions: For patients with TETs after surgical resection, advanced age, incomplete resection, WHO classification B2/B3, and higher Masaoka stage are risk factors for poor prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
PRISMA flow diagram of the literature search process. PRISMA = preferred reporting items for systematic reviews.
Figure 2.
Figure 2.
Forest plots showing 5, 10-year survival in each study. Each square represents an individual survival, with the size of the square being proportional to the weight given to the study. The dotted and dashed vertical lines represent combined survival for the whole population.
Figure 3.
Figure 3.
Overview of calculated hazard ratios (HR) for: (A) age as a continuous variable; (B) presence of myasthenia gravis; (C) incomplete resection; (D) B2/B3 than A/AB/B1; (E) stage III than stage I tumors; (F) stage IV than stage I tumors; (G) stage III/IV than stage I/II tumors; (H) stage III than stage II tumors.

References

    1. Marx A, Ströbel P, Badve SS, et al. . ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. J Thorac Oncol. 2014;9:596–611. - PubMed
    1. Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer. 2003;105:546–51. - PubMed
    1. Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol. 2010;5:S260–5. - PMC - PubMed
    1. Gatta G, van der Zwan JM, Casali PG, et al. . Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer. 2011;47:2493–511. - PubMed
    1. Conforti F, Pala L, Giaccone G, et al. . Thymic epithelial tumors: from biology to treatment. Cancer Treat Rev. 2020;86:102014. - PubMed

Supplementary concepts